Vedanta Downsizes by 20% After Phase II Stumble in Ulcerative Colitis
Vedanta is parting ways with 23 employees, or approximately 20% of its headcount, after Phase II data for microbiome therapy VE202 failed to demonstrate significant response rates in patients with ulcerative colitis.
Vedanta Downsizes by 20% After Phase II Stumble in Ulcerative Colitis Read More »
